tbuckley/cabot-search huggingface dataset:
PTH-127 Prevalence of joint hypermobility syndrome in patients with functional gastrointestinal disorders in an asian tertiary gastroenterology unit
Authors: Aml Ong, CH Lim, YT Wang
Journal: Gut (2017)

Introduction  Functional gastrointestinal disorders (FGID) are prevalent in the general population worldwide and constitute a large healthcare burden. Recently a high incidence of joint hypermobility syndrome (JHS) which is synonymous with Ehlers-Danlos Syndrome- Hypermobility Type, was reported in a group of patients with FGID in the United Kingdom. Our aim is to determine the prevalence of JHS among FGID patients in an Asian population.  Method  Case controlled study design was adopted. FGID patients who fulfilled the ROME III criteria for either Irritable bowel syndrome (IBS) or functional dyspepsia (FD) were recruited from the outpatient clinic of a gastroenterology unit at a teaching hospital in Singapore. The control cases were patients who were attending the clinic with other diagnoses. JHS was diagnosed based on the Revised Brighton Criteria and joint measurements were performed by blinded assessors. Symptom severity was assessed with Gastrointestinal Symptom Rating Scale(GSRS) and Quality of life with EQ-5D. In a subset of FGID patient (n=27), gastrointestinal transit time(GIT) was measured using wireless motility capsule and small intestinal bacterial overgrowth was measured with glucose hydrogen breath test (HBT). T-test was used to assess continuous variables and Fisher exact test for categorical variables.  Results  130 FGID patients and 79 controls (most common diagnoses were chronic hepatitis B and non- alcoholic fatty liver disease) were recruited between 1 st January 2014 and 20th January 2016. There were more females in the FGID group 69% vs Control Group 32% (p-value  109 FGID and 78 controls with completed data were analysed. JHS is more prevalent among the FGID 13%, there was no JHS among the controls (p=0.001).  FGID diagnoses among JHS patients were: FD (JHS 14% Vs 39% non-JHS, p=0.035), IBS (29% Vs 25%, p=0.81) and Overlap (57% Vs 36%, p=0.16). 14% of JHS patients reported severe pain (GSRS ≥4) Vs 6% in non-JHS (non-significant). Quality of life (EQ-5D) was similar between the 2 groups.  GIT was abnormal in 66% (2/3) of JHS Vs 55% (13/24) (p=0.69) in non-JHS. 33%( 1/3) JHS Vs 21%( 5/24) (p=0.64) non-JHS had positive HBT.  Conclusion  JHS is more prevalent among FGID patients in a predominant Chinese cohort in an Asian tertiary gastroenterology unit compared to a control group and these patients appear to have abnormalities in transit and small intestinal bacterial overgrowth. Further studies are needed to characterise these patients further and understand the role of connective tissue in gastrointestinal function.  Disclosure of Interest  None Declared
Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.
Authors: Mohammad Azam, William C. Shakespeare, Chester Metcalf, Yihan Wang, Raji Sunderamoorthi, Xiaotan Zhu, Wei-Sheng Huang, Dong Zou, Mathew Thomas, Jan Romero, Jeff Keats, Qihang Xu, David Dalgarno, Tim Clackson, Tomi K. Sawyer, George Q. Daley
Journal: Blood (2006)
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)
Authors: K. Kubota, A. Miyanaga, Y. Hosomi, Y. Okuma, K. Minato, S. Fujimoto, Y. Takiguchi, H. Okamoto, Y. Hattori, H. Isobe, H. Aono
Journal: Annals of Oncology (2016)
Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.
Authors: Ricardo H. Alvarez, Hagop M. Kantarjian, Carlos Bueso-Ramos, Moshe Talpaz, Susan O’Brien, Francis Giles, Mary Beth Rios, Jianqin Shan, Jorge Cortes
Journal: Blood (2004)
P09.01 Alterations of the RRAS and ERCC1 Genes at 19q13 in Gemistocytic Astrocytomas
Authors: T. Ohta, K. Yachi, T. Fukushima, T. Watanabe, H. Ohgaki
Journal: Neuro-Oncology (2016)

associated with certain baseline characteristics of patients, or with conditions that immediately precede an SE (short-term determinants).METHODS: We retrospectively investigated determinants in 642 consecutive patients with primary glioblastoma between 2005 and 2013 with SE as outcome.Univariable and multivariable analysis consisted of binary logistic regression for baseline determinants and conditional logistic regression for short-term determinants.RESULTS: SE occurred in 9.5% (n=61) of all cases.Baseline determinants associated with SE in glioblastoma patients consisted of sensory deficits at the onset of disease (adjusted odds ratio (AOR): 2.89; 95% confidence interval (CI): 1.37-6.09),epilepsy as presenting symptom (AOR: 2.61; 95% CI: 1.38-4.91)and perioperative seizure (AOR: 11.63; 95% CI: 3.09-43.72).Furthermore, postoperative radiotherapy (AOR: 0.21; 95% CI: 0.07-0.65)was a determinant associated independently with decreased risk of SE in comparison with temozolomide-chemoradiation.A short-term determinant associated with the occurrence of SE was tapering of dexamethasone doses (AOR: 18.07; 95% CI: 1.50-217.07),as compared with the non-use of dexamethasone.CONCLUSION: Certain baseline symptoms as well as the postoperative treatment strategy are associated with the risk of SE in patients with glioblastoma.The tapering of dexamethasone is associated with an increased short-term risk of SE.P08.
TMIC-21. KINOMIC PROFILING OF GLIOBLASTOMA CELLS REVEALS PLCG1 AS A COMMON PRO-SURVIVAL SIGNALING NODE UNDER RESTRICTED GLUCOSE
Authors: Kiera Walker, Nathaniel Boyd
Journal: Neuro-Oncology (2016)

Understanding the effects of tumor microenvironments on glioblastoma (GBM; grade IV astrocytoma) is required to develop anti-tumor treatments that will be effective in vivo. Physiologic levels of glucose are not modeled in traditional cell culture conditions and can be restricted in tumor niches. Our prior data demonstrated that nutrient restriction promotes phenotypes associated with a highly tumorigenic and therapy resistant subset of GBM cells called brain tumor initiating cells (BTICs). We therefore sought to profile the differences in kinase activity in GBM cells cultured in restricted glucose to identify pathways that could be targeted with small molecule inhibitors. Using the PamStation12 platform, we examined the ability of protein lysates from standard and low glucose cultured GBM cells to phosphorylate 144 tyrosine and 144 serine and threonine phosphorylatable peptides that correspond to phosphorylation sites in known proteins. When results from a classical and proneural xenograft were compared, we determined common changes to peptides corresponding to Phospholipase C, Gamma 1 (PLCG1) and Raf1 peptides. Using PLC and Raf inhibitors, we found a significantly stronger growth inhibitory effect of the PLC inhibitor U73122 under restricted glucose conditions. In contrast, Raf inhibitors were significantly growth inhibitory regardless of the nutrient level tested. Together, our data demonstrate that kinase activity is altered in low glucose conditions in GBM and that kinomic profiling can assist with the identification of effective strategies to target the tumor microenvironment.
Two cases of pulmonary MALT lymphoma observed single consolidation containing air bronchograms
Authors: Kiyoaki Uryu, Genju Koh, Michihiro Nin, Yosie Iwasaki, Mika Kusanagi, Chihiro Konisi, Nobuko Matsuura, Kenichi Yamasita, Katuyuki Aozasa, Hiromasa Harada
Journal: Annals of Oncology (2016)
The development of a narrow target gene panel makes next generation sequencing effective for circulating free DNA analysis
Authors: U. Malapelle, C. Mayo, D. Rocco, M. Garzon, P. Pisapia, R. Sgariglia, C. De Luca, N.J. Ariza, F. Pepe, D.M. Espinosa, A.M. Bueno, M. González-Cao, N. Karachaliou, S. Viteri, M.A. Molina Vila, R. Rosell, G. Troncone
Journal: Annals of Oncology (2016)
SURG-39. SURGICAL RESECTION OF GLIOBLASTOMA IN ELDERLY PATIENTS: THE POTENTIAL ROLE OF 5-ALA FLUORESCENCE GUIDANCE
Authors: Carmine Carapella, Veronica Villani
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most common primary brain tumor in adults and commonly occurs in individuals aged 65 years or older. The prognosis of elderly patients with GBM is universally poor: their median survival ranges from 4 to 9 months. The main reason is that older patients are often treated more conservatively than younger; this is a result of reluctance to offer aggressive treatment for fear of postoperative complications. Several series report that the 5-ALA fluorescence-guided resection increases the extension of tumor removal, improving survival. The aim of this study is to evaluate the impact of 5-ALA on outcomes in elderly GBM. The present experience is related to 36 patients (32 newly diagnosed and 4 recurrent GBM). At diagnosis the age ranged from 65 to 79 years. Co-morbidities (CM) were identified with CIRS scale. All the patients have been submitted to radiotherapy and/or chemotherapy; second and in some cases third line treatments were utilized in recurrent cases. Follow-up ranged from 1 year to 2 years. In more than 90 % of patients tumour tissue showed intraoperative red fluorescence; mainly in recurrent GBM, when MRI documented heterogeneous lesions with enhancing areas mixed with gliotic scars, fluorescence-guided surgery allowed a better definition of active tumor, with net margins from perilesional “healthy” brain. Early postoperative MRI confirmed gross total resection without contrast enhancement in 80 % of patients. In the present experience the procedure did not determine any relevant additional deficit. The median OS was 18 months with a rate of survival at 2 years of 35%. 5-ALA fluorescence-guided surgery improves tumor detection and allows extended resection of GBM in elderly. Postoperatively, there is no impact on neurological status or CM, with a consistent effect on overall survival. The evaluation of CM should drive the therapeutic decisions in elderly patients affected with GBM.
Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials
Authors: K. Goey, S. Elias, A. Hinke, M. van Oijen, C. Punt, S. Hegewisch Becker, D. Arnold, M. Koopman
Journal: Annals of Oncology (2016)
Implications from Studies with Physical Carcinogens
Authors: Paul S. Henshaw
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Implications from Studies with Physical Carcinogens Get access Paul S. Henshaw Paul S. Henshaw Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 6, June 1945, Pages 419–436, https://doi.org/10.1093/jnci/5.6.419 Published: 01 June 1945
Effect of clarithromycin add-on therapy for patients with lenalidomid-resistant multiple myeloma
Authors: Shogo Miura, Hiroyuki Kuroda, Michiko Yamada, Ken Sato, Hiroto Horiguchi, Takanori Shibata, Naoki Uemura, Tomoyuki Abe, Shigeyuki Fujii, Masahiro Maeda, Junji Kato
Journal: Annals of Oncology (2016)
Superdonors Have Decreased Iron Stores but Can Repeatedly Donate Whole Blood through Use of Iron Supplements and Decreased Serum Hepcidin Concentration.
Authors: Alan E. Mast, Tisha Foster, Holly L. Pinder, Craig A. Beczkiewicz, Daniel B. Bellissimo, Anthony T. Murphy, Steve Kovacevic, Victor J. Wroblewski, Derrick R. Witcher
Journal: Blood (2007)
GENT-26. FUNCTIONALLY CLUSTERED microRNAs FOR GBM REPROGRAMMING AND THERAPY
Authors: Pierpaolo Peruzzi, Vivek Bhaskaran
Journal: Neuro-Oncology (2016)

Deregulation of microRNAs, a class of small non-coding RNAs which work by repressing protein translation, is a hallmark of GBM. The study of their role in the tumor pathobiology, however, has been almost exclusively limited to investigating the biological effect of single microRNAs, failing to recognize the possible importance of their combinatorial action. MicroRNA expression analysis from more than 500 GBM specimens collected in the TCGA database revealed that there are a small number of microRNAs, downregulated in all tumors, whose expression is strongly correlated. The vast majority of these microRNAs are physiologically expressed together in neurons, suggesting that these “clustered” microRNAs could work as a functional network determining proper control of cellular biology and lineage determination. Consequently, we found that stepwise re-expression of a progressively increasing number of these “clustered” neuronal microRNAs in patient-derived GBM stem cells (GSCs) expands the number of targeted oncogenic proteins, including several proteins involved in epigenetic control of gene expression and maintenance of stemness. In comparison to single microRNAs, combinatorial re-expression of multiple neuron specific microRNAs resulted in a greater ability to induce differentiation toward a more benign neuronal phenotype, and decreased proliferation and tumorigenicity in vivo. Importantly, we also show that it is possible to engineer an artificial polycistronic microRNA cluster to simultaneously encode multiple neuronal microRNAs, thus creating a novel GSC-reprogramming construct. This artificial gene can be successfully delivered to GSCs by lentiviral vectors, resulting in proper expression of the multiple microRNAs and consequent profound biological effects. We provide for the first time evidence that microRNAs work as functional clusters in GBM, and should be studied accordingly in the contest of tumor pathobiology. Also, this study demonstrates the feasibility of a novel multi-gene therapy approach to GBM, based on unique features of microRNAs, which inlcude their small size, simple biogenesis, and broad molecular targeting.
Leukocytosis and Thrombosis At Diagnosis Are Associated with Poor Survival in Polycythemia Vera: A Population-Based Study on 327 Patients
Authors: Francois Girodon, Khadija Abdulkarim, Gilles Bonicelli, Peter Johansson, Valérie Jooste, Björn Andreasson, Morgane Mounier, Marc Maynadie
Journal: Blood (2011)
Uncover TET1 Targets in MLL -Rearranged Leukemia
Authors: Hengyou Weng, Huilin Huang, He Huang, Okwang Kwon, Ping Chen, Xi Jiang, Chao Hu, Hao Huang, Yungui Wang, Xi Qin, Stephen Arnovitz, Shenglai Li, Jennifer Strong, Rui Su, Mary Beth Neilly, Zejuan Li, Yingming Zhao, Jianjun Chen
Journal: Blood (2015)
Therapeutically Infused Redirected T Cells Targeting WT1 Successfully Inhibited Leukemia Stem Cells in Vivo
Authors: Hiroaki Asai, Hiroshi Fujiwara, Toshiki Ochi, Yukihiro Miyazaki, Fumihiro Ochi, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa
Journal: Blood (2012)
RARE-22. MEDULLOBLASTOMA IN A CHILD WITH NEUROFIBROMATOSIS-1: CASE REPORT AND REVIEW
Authors: Magimairajan Issai Vanan, Patrick McDonald, Sandra Marles, Patrick Frosk, Sherry Krawitz, Halley Moffat
Journal: Neuro-Oncology (2016)

Neurofibromatosis-1(NF-1) is a relatively common inherited cancer predisposition syndrome and patients with NF-1 are prone to develop benign and malignant tumors of the CNS and peripheral nervous system, in addition to malignant diseases affecting other parts of the body. Medulloblastoma (MBL), the most common malignant brain tumor of childhood, is rarely associated with NF-1. We report a case of Medulloblastoma in a genetically proven case of NF-1.Our patient was diagnosed to have NF-1 in infancy based on clinical / radiological features (Café-au-lait macules, axillary freckling, cutaneous / plexiform neurofibromas and sphenoid wing dysplasia).In the past 2 years prior to presentation she started having intermittent episodes of dizziness and ataxia which gradually worsened and was associated with headache and vomiting. MRI of the brain revealed a midline posterior fossa mass originating from the floor of the fourth ventricle. She underwent a complete surgical resection of the mass and pathology was suggestive of Medulloblastoma. Immunohisto-chemistry for the mismatch repair defect genes (MLH1, MSH2, MSH6 and PMS2) stained positive in both the tumor and adjacent normal brain tissue. Genetic testing revealed mutation in the NF-1 gene. She was treated as per COG ACNS0331 protocol and is currently in remission at 6 months follow up after completion of chemotherapy. A review of the literature identified three case reports of Medulloblastoma in NF-1 patients.
JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics
Authors: Anna Guadall, Elodie Lesteven, Gil Letort, Sarah Awan Toor, Doriane Pognant, Megane Brusson, Emmanuelle Verger, Jerome Larghero, Valerie Vanneaux, Christine Chomienne, Wassim El Nemer, Bruno Cassinat, Jean-Jacques Kiladjian
Journal: Blood (2016)
ACTR-13. NEUTROPHIL TO LYMPHOCYTE COUNT RATIO IN ELDERLY PATIENTS WITH GLIOBLASTOMA
Authors: Masaki Okada, Daisuke Ogawa
Journal: Neuro-Oncology (2016)

An emerging biomarker, neutrophil to lymphocyte count ratio (NLR), is considered to indicate the prognosis of many cancers. Significance of NLR in patients with malignant glioma has not been studied well, especially in elderly patients that have poor prognosis in nature. 26 patients of malignant glioma above 70 years-old treated in our hospital from 2006.12 to 2016.4 were included. Mean age was 75.9 years (range: 70–86 years). WHO grade III: 7 cases and grade IV: 19 cases were included. We investigated NLR (cut off:3.7), CRP and Karnofsky Performance Status (KPS, cut off: 70) at initial presentation in relation to histological grade and overall survival. Overall survival of all cases was 12.3 months, WHO grade III: 53.5 months and grade IV:12.1 months. We could not find any relationship between NLR and WHO grade. NLR did not relate to overall survival. NLR had weak correlation to KPS. Poor KPS group demonstrated short overall survival. CRP correlated to NLR and KPS (r=0.524 and r=0.441, respectively), though, this correlation was not observed when cases were limited in normal CRP group (<0.2mg/dL). Patients underwent surgical excision demonstrated longer survival in contrast to patients with biopsy, while no difference was observed in NLR between both groups. Patients of good KPS at initial presentation underwent standard radiation therapy and demonstrated long survival. Patients with poor KPS were treated without chemotherapy. NLR is easily affected by systemic inflammation. Elderly patients are prone to have poor physical conditions prior to the presentation, which might reflect on higher NLR. Our study could not discover the relationship between NLR and treatment outcome and histological grade. Further study is needed to elucidate the significance of NLR in elderly patients with malignant glioma.
A data collection representative of an outcome analysis in advanced Non Small Cell Lung Cancer (NSCLC) expressing EGFR mutations after failure of first line therapy with Tyrosine Kinase Inhibitors (TKIs) with careful on post progression survival
Authors: C. Sergi, O. Commendatore, G. Burrafato, C. Martines, S. Garozzo, S. Cordio, D. Sambataro, D. Cinà, S. Miraponte, R. Bordonaro
Journal: Annals of Oncology (2016)
The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG)
Authors: Roman Hájek, Jiri Jarkovsky, Walter Bouwmeester, Maarten Treur, DeCosta Lucy, Marco Campioni, Michel Delforge, Marc S. Raab, Paul Schoen, Zsolt Szabo, Sebastian Gonzalez-McQuire
Journal: Blood (2016)
Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression
Authors: J.S. Ross, L.M. Gay, J.A. Elvin, J. Suh, J.-A. Vergilio, S. Ramkissoon, S. Ali, V.A. Miller, P.J. Stephens
Journal: Annals of Oncology (2016)
Augmented Therapy Based on PCR-MRD Levels of Children with Acute Lymphoblastic Leukemia: A Report from the Japanese Children’s Cancer and Leukemia Study Group ALL 2000 MRD Pilot Study
Authors: Toshinori Hori, Kazutaka Yamaji, Shohei Yokota, Tomoko Okamoto, Arata Watanabe, Atsushi Kikuta, Keiko Asami, Yasuo Horikoshi, Nobuyuki Hyakuna, Takashi Taga, Keiko Nomura, Asayuki Iwai, Tsutomu Watanabe, Takuya Yanase, Yutaka Saikawa, Akira Kamitamari, Takeji Matsushita, Yasuto Shimomura, Masahito Tsurusawa
Journal: Blood (2008)
Power of fecal DNA methylation analysis: Does it lead to development of a noninvasive screening tool for pancreatic cancer?
Authors: T. Nagasaka, A. Goel, N. Taniguchi, Y. Mori, K. Sigeyasu, E. Yamada, T. Oka, D. Sun, T. Fujiwara
Journal: Journal of Clinical Oncology (2011)

187 Background: The development of noninvasive screening tests is important to reduce mortality from gastrointestinal neoplasia, especially given that there is no noninvasive screening test for pancreatic cancer. We sought to develop such a test by analysis of DNA methylation from exfoliated cancer cells in feces. Methods: We had reported a novel strategy that uses single-step modification of DNA with sodium bisulfite and fluorescence polymerase chain reaction methodology to measure aberrant methylation in fecal DNA. We increased number of biomarkers from 4 to 8 that were analyzed in 144 fecal samples obtained from a variety of patients, including colorectal tumors, hepatic tumors, and pancreatic tumors. Results: The assay successfully identified one or more methylated markers in fecal DNA from patients with colorectal cancer, polyps, hepatocellular carcinoma, metastatic colorectal cancer at liver, and pancreatic cancer. Conclusions: Methylation of 8 biomarkers in fecal DNA is associated with the presence of gastroenterological tumors relative to non-neoplastic conditions. Our fecal DNA methylation assay provides a possible means to noninvasively screen not only for colorectal tumors but also for pancreatic tumors. No significant financial relationships to disclose.
Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases
Authors: M. van den Eynde, B. Mlecnik, G. Bindea, J.-P. Machiels, A. Jouret-Mourin, P. Baldin, A. Kartheuser, D. Leonard, C. Remue, J.-F. Gigot, C. Hubert, Y. Humblet, N. Haicheur, F. Marliot, F. Pagès, J. Galon
Journal: Annals of Oncology (2016)